Product

Ubrogepant - API

Product Name Ubrogepant - API
Product Code DA-U026-a
Chemical name Ubrogepant
Synonyms (S)-N-((3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide; (3′S)-1′,2′,5,7-Tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2′-oxospiro[6H-cyclopenta[b]pyridine-6,3′-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide; Ubrelvy;
Impurity NA
CAS Number 1374248-77-7
Alternate CAS # NA
Molecular form C29H26F3N5O3
Appearance NA
Melting Point NA
Mol. Weight 549.55
Storage 2-8°C Refrigerator
Solubility NA
Stability NA
Category metabolites,pharmaceutical standards,intermediates,Fine Chemicals
Boiling Point NA
Applications Ubrogepant is an oral CGRP antagonist used in the acute treatment of migraine with or without aura.Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults.5 It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.6 Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and rimegepant remain in clinical development
Dangerous Goods Info NA
References NA
Extra Notes NA
Documents (MSDS) No Data Available
Keywords NA
Product Packings